Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

Breast Cancer Cells ◽

Triple Negative ◽

Parp Inhibitor ◽

Deacetylase Inhibitor ◽

Inhibitor Treatment

Abstract 5847: A histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth with apoptosis in triple-negative breast cancer cells

10.1158/1538-7445.am2018-5847 ◽

2018 ◽

Author(s):

Hisako Ono ◽

Yoshihiro Sowa ◽

Yosuke Iizumi ◽

Mano Horinaka ◽

Tetsuya Taguchi ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Cells ◽

Histone Deacetylase ◽

Breast Cancer Cells ◽

Triple Negative ◽

Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-14-0778 ◽

2015 ◽

Vol 14 (8) ◽

pp. 1848-1857 ◽

Cited By ~ 41

Author(s):

Amanda Schech ◽

Armina Kazi ◽

Stephen Yu ◽

Preeti Shah ◽

Gauri Sabnis

Keyword(s):

Breast Cancer ◽

Cancer Cells ◽

Histone Deacetylase ◽

Breast Cancer Cells ◽

Triple Negative ◽

Tumor Initiating Cells ◽

Histone deacetylase inhibitor 2-hexyl-4-pentynoic acid enhances hydroxyurea therapeutic effect in triple-negative breast cancer cells

Mutation Research/Genetic Toxicology and Environmental Mutagenesis ◽

10.1016/j.mrgentox.2021.503422 ◽

2021 ◽

pp. 503422

Author(s):

Chenxia Ding ◽

Benyu Su ◽

Qiaoling Li ◽

Wenwen Ding ◽

Guochao Liu ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Cells ◽

Histone Deacetylase ◽

Therapeutic Effect ◽

Breast Cancer Cells ◽

Triple Negative ◽

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

Breast Cancer Research ◽

10.1186/bcr3192 ◽

2012 ◽

Vol 14 (3) ◽

Cited By ~ 141

Author(s):

Chandra R Tate ◽

Lyndsay V Rhodes ◽

H Chris Segar ◽

Jennifer L Driver ◽

F Nell Pounder ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Cells ◽

Histone Deacetylase ◽

Breast Cancer Cells ◽

Triple Negative ◽

The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-4815-x ◽

2018 ◽

Vol 171 (1) ◽

pp. 43-52 ◽

Cited By ~ 6

Author(s):

Hisako Ono ◽

Yoshihiro Sowa ◽

Mano Horinaka ◽

Yosuke Iizumi ◽

Motoki Watanabe ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Cells ◽

Histone Deacetylase ◽

Breast Cancer Cells ◽

Triple Negative ◽

Mapk Pathway ◽

Abstract PO-218: Molecular profiling of basal 2 subtypes of triple negative breast cancer cells and their response to a histone deacetylase inhibitor

10.1158/1538-7755.disp20-po-218 ◽

2020 ◽

Author(s):

Beverly Word ◽

Ebony Cotton ◽

George Hammons ◽

Beverly Lyn-Cook ◽

Density Stovall

Keyword(s):

Breast Cancer ◽

Cancer Cells ◽

Histone Deacetylase ◽

Breast Cancer Cells ◽

Triple Negative ◽

Molecular Profiling ◽

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells

Breast Cancer Research ◽

10.1186/s13058-015-0534-y ◽

2015 ◽

Vol 17 (1) ◽

Cited By ~ 78

Author(s):

Ahrum Min ◽

Seock-Ah Im ◽

Debora Keunyoung Kim ◽

Sang-Hyun Song ◽

Hee-Jun Kim ◽

...

Keyword(s):

Breast Cancer ◽

Histone Deacetylase ◽

Hydroxamic Acid ◽

Breast Cancer Cells ◽

Triple Negative ◽

Parp Inhibitor ◽

Suberoylanilide Hydroxamic Acid ◽

Abstract B125: Molecular profiling basal 2 subtypes of triple-negative breast cancer cells and their response to histone deacetylase inhibitor

10.1158/1538-7755.disp19-b125 ◽

2020 ◽

Author(s):

Beverly Lyn-Cook ◽

Destiny Stovall ◽

Beverly Word ◽

Ebony Cotton ◽

George Hammons

Keyword(s):

Breast Cancer ◽

Cancer Cells ◽

Histone Deacetylase ◽

Breast Cancer Cells ◽

Triple Negative ◽

Molecular Profiling ◽

Abstract 1011: Induction of ‘BRCAness’ by treatment with histone deacetylase inhibitors sensitizes human triple negative breast cancer cells to PARP inhibitor and cisplatinum.

10.1158/1538-7445.am2013-1011 ◽

2013 ◽

Author(s):

Warren C. Fiskus ◽

Rekha Rao ◽

Soumyasri Das Gupta ◽

Lata Chauhan ◽

Kapil N. Bhalla

Keyword(s):

Breast Cancer ◽

Cancer Cells ◽

Histone Deacetylase ◽

Breast Cancer Cells ◽

Histone Deacetylase Inhibitors ◽

Triple Negative ◽

Parp Inhibitor

Abstract 3481: Sigma-2 ligands sensitize triple negative breast cancer cells to PARP inhibitor treatment

10.1158/1538-7445.am2015-3481 ◽

2015 ◽

Author(s):

Chenbo Zeng ◽

Julia Mankoff ◽

Robert H. Mach

Keyword(s):

Breast Cancer ◽

Cancer Cells ◽

Breast Cancer Cells ◽

Triple Negative ◽

Parp Inhibitor ◽

Inhibitor Treatment